Skip to main content
Key Specialties
Cardiology Diabetology Endocrinology Gastroenterology Geriatrics and Gerontology Gynecology and Obstetrics Hematology Infectious Disease Internal Medicine Nephrology Neurology Oncology Pediatrics Respiratory Medicine Rheumatology Surgery
Congress Coverage
2024 ACC Congress 2023 ESMO Congress 2023 EASD Congress 2023 ERS Congress 2023 ESC Congress
Clinical Collections
Advances in Alzheimer’s

At a glance: The STEP trials

A round-up of the STEP phase 3 clinical trials evaluating semaglutide for weight loss in people with overweight or obesity.
ADVANCED SEARCH
Log in
Top
Clinical Reviews in Allergy & Immunology
Published in: Clinical Reviews in Allergy & Immunology 2/2013

01-04-2013

Inflammation, Atherosclerosis, and Psoriasis

Authors: David Siegel, Sridevi Devaraj, Anupam Mitra, Siba P. Raychaudhuri, Smriti K. Raychaudhuri, Ishwarlal Jialal

Published in: Clinical Reviews in Allergy & Immunology | Issue 2/2013

Login to get access

Abstract

Increasing evidence supports an important role for inflammation in all phases of atherosclerosis, from initiation of the fatty streak to final culmination in acute coronary syndromes. Numerous inflammatory biomarkers including cell adhesion molecules, cytokines, chemokines, and acute-phase reactants such as fibrinogen, serum amyloid A, and C-reactive protein (CRP) have been shown to predict cardiovascular (CVD) events. Several prospective studies have shown a consistent and robust relationship between levels of high-sensitivity CRP and the risk of future CVD events. Toll-like receptors are pattern recognition receptors and members of the innate immune system that contribute to inflammation and appear to play key roles in atherosclerosis. Lipoprotein-associated phospholipase A2 may also be an independent CVD risk factor. Psoriasis has been associated with an increasing risk for atherosclerosis, including coronary artery disease and stroke. Patients with psoriasis have a 5-year shorter life expectancy, most frequently due to CVD. Psoriasis is associated with a chronic inflammatory state and with elevated levels of CRP and other inflammatory cytokines and these may play a causative role in the increased risk of psoriatic patients for CVD. Patients with psoriasis may represent an emerging risk population and patients with moderate to severe psoriasis should be screened and aggressively treated for CVD risk factors.
Literature
1.
2.
Hansson GK, Libby P (2006) The immune response in atherosclerosis: a double-edged sword. Nat Rev Immunol 6:508–19PubMedCrossRef
3.
Jialal I, Devaraj S (2001) Inflammation and atherosclerosis: the value of the high-sensitivity C-reactive protein assay as a risk marker. Am J Clin Pathol 116:S108–15PubMed
4.
Libby P, Okamoto Y, Rocha VZ, Folco E (2010) Inflammation in atherosclerosis: transition from theory to practice. Circ J 74:213–20PubMedCrossRef
5.
Packard RR, Lichtman AH, Libby P (2009) Innate and adaptive immunity in atherosclerosis. Semin Immuno Pathol 31:5–22CrossRef
6.
Verma S, Szmitko PE, Ridker PM (2005) C-reactive protein comes of age. Nat Clin Pract Cardiovasc Med 2:29–36PubMedCrossRef
7.
Verma S, Devaraj S, Jialal I (2006) Is C-reactive protein an innocent bystander or proatherogenic culprit? C-reactive protein promotes atherothrombosis. Circulation 113:2135–50PubMed
8.
Devaraj S, Singh U, Jialal I (2009) The evolving role of C-reactive protein in atherothrombosis. Clin Chem 55:229–38PubMedCrossRef
9.
10.
11.
12.
Hill HR, Hogan NA, Rallison ML, Santos JI, Charette RP, Kitahar M (1982) Functional and metabolic abnormalities of diabetic monocytes. Adv Expt Med Biol 69:621–8CrossRef
13.
Devaraj S, Dasu MR, Rockwood J, Winter W, Griffen SC, Jialal I (2008) Increased toll-like receptor (TLR) 2 and TLR4 expression in monocytes from patients with type 1 diabetes: further evidence of a proinflammatory state. J Clin Endocrinol Metab 93:578–3PubMedCrossRef
14.
Dasu MR, Devaraj S, Park S, Jialal I (2010) Increased toll-like receptor activation and TLR ligands in recently diagnosed type 2 diabetes subjects. Diabetes Care 33:861–8PubMedCrossRef
15.
16.
17.
Ohashi K, Burkart V, Flohe S, Kolb H (2000) Cutting edge: heat shock protein 60 is a putative endogenous ligand of the toll-like receptor-4 complex. J Immunol 164:558–61PubMed
18.
19.
Noble PW, McKee CM, Cowman M, Shin HS (1996) Hyaluronan fragment activate an NF-κB/I-κBα autoregulatory loop in murine macrophages. J Exp Med 183:2373–8PubMedCrossRef
20.
Akashi S, Shimazu R, Ogata H, Nagai Y, Takeda K, Kimoto M, Miyake K (2000) Cutting edge: cell surface expression and lipopolysaccharide signaling via the toll-like receptor 4-MD-2 complex on mouse peritoneal macrophages. J Immunol 164:3471–5PubMed
21.
Mohammad MK, Morran M, Slotterbeck B, Leaman DW, Sun Y, Grafenstein H, Hong SC, McInerney MF (2006) Dysregulated toll-like receptor expression and signaling in bone marrow-derived macrophages at the onset of diabetes in the non-obese diabetic mouse. Int Immunol 18:1101–13PubMedCrossRef
22.
Song MJ, Kim KH, Yoon JM, Kim JB (2006) Activation of toll-like receptor 4 is associated with insulin resistance in adipocytes. Biochem Biophys Res Commun 346:739–45PubMedCrossRef
23.
Liu X, Ukai T, Yumoto H, Davey M, Goswami S, Gibson FC 3rd, Genco CA (2007) Toll-like receptor 2 plays a critical role in the progression of atherosclerosis that is independent of dietary lipids. Atherosclerosis 196:146–54PubMedCrossRef
24.
Michelsen KS, Wong MH, Shah PK, Zhang W, Yano J, Doherty TM, Akira S, Rajavashisth TB, Arditi M (2004) Lack of toll-like receptor 4 or myeloid differentiation factor 88 reduces atherosclerosis and alters plaque phenotype in mice deficient in apolipoprotein E. Proc Natl Acad Sci USA 101:10679–84PubMedCrossRef
25.
Bjorkbacka H, Kunjathoor VV, Moore KJ, Koehn S, Ordija CM, Lee MA, Means T, Halmen K, Luster AD, Golenbock DT, Freeman MW (2004) Reduced atherosclerosis in MyD88-null mice links elevated serum cholesterol levels to activation of innate immunity signaling pathways. Nat Med 10:416–21PubMedCrossRef
26.
Edfeldt K, Swedenborg J, Hansson GK, Yan ZQ (2002) Expression of toll-like receptors in human atherosclerotic lesions: a possible pathway for plaque activation. Circulation 105:1158–61PubMed
27.
Leemans JC, Stokman G, Claessen N, Rouschop KM, Teske GJ, Kirschning CJ, Akira S, van der Poll T, Weening JJ, Florquin S (2005) Renal associated TLR2 mediates ischemia/reperfusion injury in the kidney. J Clin Invest 115:2894–903PubMedCrossRef
28.
Favre J, Musette P, Douin-Echinard V, Laude K, Henry JP, Arnal JF, Thuillez C, Richard V (2007) Toll-like receptors 2-deficient mice are protected against postischemic coronary endothelial dysfunction. Arterioscler Thromb Vasc Biol 27:1064–71PubMedCrossRef
29.
Kuwahata S, Fujita S, Orihara K, Hamasaki S, Oba R, Hirai H, Nagata K, Ishida S, Kataoka T, Oketani N, Ichiki H, Iriki Y, Saihara K, Okui H, Ninomiya Y, Tei C (2010) High expression level of Toll-like receptor 2 on monocytes is an important risk factor for arteriosclerotic disease. Atherosclerosis 209:248–54PubMedCrossRef
30.
Mizoguchi E, Orihara K, Hamasaki S, Ishida S, Kataoka T, Ogawa M, Saihara K, Okui H, Fukudome T, Shinsato T, Shirasawa T, Ichiki H, Kubozono T, Ninomiya Y, Otsuji Y, Tei C (2007) Association between toll-like receptors and the extent and severity of coronary artery disease in patients with stable angina. Coron Artery Dis 18:31–8PubMedCrossRef
31.
Monaco C, Gregan SM, Navin TJ, Foxwell BM, Davies AH, Feldmann M (2009) Toll-like receptor-2 mediates inflammation and matrix degradation in human atherosclerosis. Circulation 120:2462–9PubMedCrossRef
32.
Caso JR, Pradillo JM, Hurtado O, Lorenzo P, Moro MA, Lizasoain I (2007) Toll-like receptor 4 is involved in brain damage and inflammation after experimental stroke. Circulation 115:1599–608PubMedCrossRef
33.
Ameziane N, Beillat T, Verpillat P, Chollet-Martin S, Aumont MC, Seknadji P, Lamotte M, Lebret D, Ollivier V, de Prost D (2003) Association of the toll-like receptor 4 gene Asp299Gly polymorphism with acute coronary events. Arterioscler Thromb Vasc Biol 23:e61–4PubMedCrossRef
34.
Fukushima R, Soejima H, Fukunaga T, Nakayama M, Oe Y, Oshima S, Sugiyama S, Ogawa H (2009) Expression levels of toll-like receptor genes in coronary atherosclerotic lesions of patients with acute coronary syndrome or stable angina pectoris. Circ J 73:1479–84PubMedCrossRef
35.
Bajaj M, Suraamornkul S, Piper P, Hardies LJ, Glass L, Cersosimo E, Pratipanawatr T, Miyazaki Y, DeFronzo RA (2004) Decreased plasma adiponectin concentrations are closely related to hepatic fat content and hepatic insulin resistance in pioglitazone-treated type 2 diabetic patients. J Clin Endocrinol Metab 89:200–6PubMedCrossRef
36.
Thompson D, Pepys MB, Wood SP (1999) The physiological structure of human C-reactive protein and its complex with phosphocholine. Structure 7:169–77PubMedCrossRef
37.
Khreiss T, József L, Potempa LA, Filep JG (2005) Loss of pentameric symmetry in C-reactive protein induces interleukin-8 secretion through peroxynitrite signaling in human neutrophils. Circ Res 97:690–7PubMedCrossRef
38.
Calabro P, Willerson JT, Yeh ET (2003) Inflammatory cytokines stimulated C-reactive protein production by human coronary artery smooth muscle cells. Circulation 108:1930–2PubMedCrossRef
39.
Yasojima K, Schwab C, McGeer EG, McGeer PL (2001) Generation of C-reactive protein and complement components in atherosclerotic plaques. Am J Pathol 158:1039–51PubMedCrossRef
40.
Kobayashi S, Inoue N, Ohashi Y, Terashima M, Matsui K, Mori T, Fujita H, Awano K, Kobayashi K, Azumi H, Ejiri J, Hirata K, Kawashima S, Hayashi Y, Yokozaki H, Itoh H, Yokoyama M (2003) Interaction of oxidative stress and inflammatory response in coronary plaque instability: important role of C-reactive protein. Arterioscler Thromb Vasc Biol 23:1398–404PubMedCrossRef
41.
Dong Q, Wright JR (1996) Expression of C-reactive protein by alveolar macrophages. J Immunol 156:4815–20PubMed
42.
Venugopal SK, Devaraj S, Jialal I (2005) Macrophage conditioned medium induces the expression of C-reactive protein in human aortic endothelial cells: potential for paracrine/autocrine effects. Am J Pathol 166:1265–71PubMedCrossRef
43.
Ouchi N, Kihara S, Funahashi T, Nakamura T, Nishida M, Kumada M, Okamoto Y, Ohashi K, Nagaretani H, Kishida K, Nishizawa H, Maeda N, Kobayashi H, Hiraoka H, Matsuzawa Y (2003) Reciprocal association of C-reactive protein with adiponectin in blood stream and adipose tissue. Circulation 107:671–4PubMedCrossRef
44.
Devaraj S, Torok N, Dasu MR, Samols D, Jialal I (2008) Adiponectin decreases C-reactive protein synthesis and secretion from endothelial cells: evidence for an adipose tissue vascular loop. Arterioscler Thromb Vasc Biol 28:1368–74PubMedCrossRef
45.
Singh P, Hoffmann M, Wolk R, Shamsuzzaman AS, Somers VK (2007) Leptin induces C reactive protein expression in vascular endothelial cells. Arterioscler Thromb Vasc Biol 27:e302–7PubMedCrossRef
46.
Bassuk SS, Rifai N, Ridker PM (2004) High-sensitivity C-reactive protein: clinical importance. Curr Probl Cardiol 29(8):439–93PubMed
47.
Pearson TA, Mensah GA, Alexander RW, Anderson JL, Cannon RO, Criqui M, Fadl Y, Fortmann SP, Hong Y, Myers GL, Rifai N, Smith SC, Taubert K, Tracy RP, Vinicor F (2003) Markers of inflammation and cardiovascular disease. Application to clinical and public health practice. Circulation 107:499–511PubMedCrossRef
48.
Devaraj S, Du Clos TW, Jialal I (2005) Binding and internalization of C-reactive protein by Fcgamma receptors on human aortic endothelial cells mediates biological effects. Arterioscler Thromb Vasc Biol 25:1359–63PubMedCrossRef
49.
Ridker PM, Danielson E, Fonseca FA, Genest J, Gotto AM Jr, Kastelein JJ, Koenig W, Libby P, Lorenzatti AJ, Macfadyen JG, Nordestgaard BG, Shepherd J, Willerson JT, Glynn RJ (2009) Reduction in CRP and LDL-C and cardiovascular event rates after initiation of rosuvastatin: a prospective study of the JUPITER trial. Lancet 373:1175–82PubMedCrossRef
50.
Jialal I, Devaraj S (2009) Jupiter to Earth: CRP promotes atherothrombosis. Metab Syndr Relat Disord 7:1–3PubMedCrossRef
51.
Dada N, Kim NW, Wolfert RL (2002) Lp-PLA2: an emerging biomarker of coronary heart disease. Expert Rev Mol Diagn 2:17–22PubMedCrossRef
52.
Hakkinen T, Luoma JS, Hiltunen MO, Macphee CH, Milliner KJ, Patel L, Rica SQ, Tew DG, Karkola K, Yia-Herttuala S (1999) Lipoprotein-associated phospholipase A(2), platelet-activating factor acetylhydrolase, is expressed by macrophages in human and rabbit atherosclerotic lesions. Arterioscler Thromb Vasc Biol 19:2909–17PubMedCrossRef
53.
Winkler K, Winkelmann BR, Scharnagl H, Hoffmann MM, Grawitz AB, Nauck M, Bohm BO, Marz W (2005) Platelet-activating factor acetylhydrolase activity indicates angiographic coronary artery disease independently of systemic inflammation and other risk factors: the Ludwigshafen Risk and Cardiovascular Health Study. Circulation 111:980–7PubMedCrossRef
54.
Packard CJ, O’Reilly DS, Caslake MJ, McMahon AD, Ford I, Cooney J, Macphee CH, Suckling KE, Krishna M, Wilkinson FE, Rumley A, Lowe GD (2000) Lipoprotein-associated phospholipase A2 as an independent predictor of coronary heart disease. West of Scotland Coronary Prevention Study Group. N Engl J Med 343:1148–55PubMedCrossRef
55.
Ballantyne CM, Hoogeveen RC, Bang H, Coresh J, Folsom AR, Heiss G, Sharrett AR (2004) Lipoprotein-associated phospholipase A2, high-sensitivity C-reactive protein, and risk for incident coronary heart disease in middle-aged men and women in the Atherosclerosis Risk in Communities (ARIC) study. Circulation 109:837–42PubMedCrossRef
56.
Zalewski A, Nelson JJ, Hegg L, Macphee C (2006) Lp-PLA2: a new kid on the block. Clin Chem 52:1645–50PubMedCrossRef
57.
Oei HH, Van Der Meer IM, Hofman A, Koudstaal PJ, Stijnen T, Breteler MM, Witteman JC (2005) Lipoprotein-associated phospholipase A2 activity is associated with risk of coronary heart disease and ischemic stroke: the Rotterdam Study. Circulation 111:570–5PubMedCrossRef
58.
Izaki S, Yamamoto T, Goto Y, Ishimaru S, Yudate F, Kitamura K, Matsuzaki M (1996) Platelet-activating factor and arachidonic acid metabolites in psoriatic inflammation. Br J Dermatol 134:1060–4PubMedCrossRef
59.
60.
Gladman DD, Shuckett R, Russell ML, Thorne JC, Schachter RK (1987) Psoriatic arthritis (PSA)—an analysis of 220 patients. Q J Med 62:127–41PubMed
61.
Prodanovich S, Kirsner RS, Kravetz JD, Ma F, Martinez L, Federman DG (2009) Association of psoriasis with coronary artery, cerebrovascular, and peripheral vascular diseases and mortality. Arch Dermatol 145:700–3PubMedCrossRef
62.
Kimball AB, Guerin A, Latremouille-Viau D, Yu AP, Gupta S, Bao Y, Mulani P (2010) Coronary heart disease and stroke risk in patients with psoriasis: retrospective analysis. Am J Med 123:350–7PubMedCrossRef
63.
Tobin AM, Veale DJ, Fitzgerald O, Rogers S, Collins P, O’Shea D, Kirby B (2010) Cardiovascular disease and risk factors in patients with psoriasis and psoriatic arthritis. J Rheumatol 37:1386–94PubMedCrossRef
64.
Abuabara K, Azfar RS, Shin DB, Neimann AL, Troxel AB, Gelfand JM (2010) Cause-specific mortality in patients with severe psoriasis: a population-based cohort study in the U.K. Br J Dermatol 163:586–92PubMedCrossRef
65.
Gelfand JM, Neimann AL, Shin DB, Wang X, Margolis DJ, Troxel AB (2006) Risk of myocardial infarction in patients with psoriasis. JAMA 296:1735–41PubMedCrossRef
66.
Neimann AL, Shin DB, Wang X, Margolis DJ, Troxel AB, Gelfand JM (2006) Prevalence of cardiovascular risk factors in patients with psoriasis. J Am Acad Dermatol 55:829–35PubMedCrossRef
67.
68.
Raychaudhuri SK, Chatterjee S, Nguyen C, Kaur M, Jialal I, Raychaudhuri SP (2010) Increased prevalence of the metabolic syndrome in patients with psoriatic arthritis. Metab Syndr Relat Disord 8:331–4PubMedCrossRef
69.
Love TJ, Qureshi AA, Karlson EW, Gelfand JM, Choi HK (2011) Prevalence of the metabolic syndrome in psoriasis: results from the National Health and Nutrition Examination Survey, 2003–2006. Arch Dermatol 147:419–24PubMedCrossRef
70.
Mehta NN, Azfar RS, Shin DB, Neimann AL, Troxel AB, Gelfand JM (2010) Patients with severe psoriasis are at increased risk of cardiovascular mortality: cohort study using the General Practice Research Database. Eur Heart J 31:1000–6PubMedCrossRef
71.
Han C, Robinson DW Jr, Hackett MV, Paramore LC, Fraeman KH, Bala MV (2006) Cardiovascular disease and risk factors in patients with rheumatoid arthritis, psoriatic arthritis, and ankylosing spondylitis. J Rheumatol 33:2167–72PubMed
72.
73.
Gladman DD, Ang M, Su L, Tom BD, Schentag CT, Farewell VT (2009) Cardiovascular morbidity in psoriatic arthritis. Ann Rheum Dis 68:1131–5PubMedCrossRef
74.
Balci DD, Balci A, Karazincir S, Ucar E, Iyigun U, Yalcin F, Seyfeli E, Inandi T, Egilmez E (2009) Increased carotid artery intima-media thickness and impaired endothelial function in psoriasis. J Eur Acad Dermatol Venereol 23:1–6PubMedCrossRef
75.
Tam LS, Shang Q, Li EK, Tomlinson B, Chu TT, Li M, Leung YY, Kwok LW, Wong KC, Li TK, Yu T, Zhu TY, Kun EW, Yip GW, Yu CM (2008) Subclinical carotid atherosclerosis in patients with psoriatic arthritis. Arthritis Rheum 59:1322–31PubMedCrossRef
76.
Ludwig RJ, Herzog C, Rostock A, Ochsendorf FR, Zollner TM, Thaci D, Kaufmann R, Vogl TJ, Boehncke WH (2007) Psoriasis: a possible risk factor for development of coronary artery calcification. Br J Dermatol 156:271–6PubMedCrossRef
77.
Späh F (2008) Inflammation in atherosclerosis and psoriasis: common pathogenic mechanisms and the potential for an integrated treatment approach. Br J Dermatol 159:10–7PubMedCrossRef
78.
Tam LS, Tomlinson B, Chu TT, Li M, Leung YY, Kwok LW, Li TK, Yu T, Zhu YE, Wong KC, Kun EW, Li EK (2008) Cardiovascular risk profile of patients with psoriatic arthritis compared to controls—the role of inflammation. Rheumatology (Oxford) 47:718–23CrossRef
79.
Kimball AB, Gladman D, Gelfand JM, Gordon K, Horn EJ, Korman NJ, Korver G, Krueger GG, Strober BE, Lebwohl MG (2008) National Psoriasis Foundation clinical consensus on psoriasis comorbidities and recommendations for screening. J Am Acad Dermatol 58:1031–42PubMedCrossRef
80.
Friedewald VE, Cather JC, Gelfand JM, Gordon KB, Gibbons GH, Grundy SM, Jarratt MT, Krueger JG, Ridker PM, Stone N, Roberts WC (2008) AJC editor’s consensus: psoriasis and coronary artery disease. Am J Cardiol 102:1631–43PubMedCrossRef
81.
Ouchi N, Parker JL, Lugus JJ, Walsh K (2011) Adipokines in inflammation and metabolic disease. Nat Rev Immunol 11:85–97PubMedCrossRef
82.
Olefsky JM, Glass CK (2010) Macrophages, inflammation, and insulin resistance. Annu Rev Physiol 72:219–46PubMedCrossRef
83.
Florez H, Castillo-Florez S, Mendez A, Casanova-Romero P, Larreal-Urdaneta C, Lee D, Goldberg R (2006) C-reactive protein is elevated in obese patients with the metabolic syndrome. Diabetes Res Clin Pract 71:92–100PubMedCrossRef
84.
Raychaudhuri SP, Jiang WY, Raychaudhuri SK (2008) Revisiting the Koebner phenomenon: role of NGF and its receptor system in the pathogenesis of psoriasis. Am J Pathol 172:961–71PubMedCrossRef
85.
Matarese G, Di Giacomo A, Sanna V, Lord GM, Howard JK, Di Tuoro A, Bloom SR, Lechler RI, Zappacosta S, Fontana S (2001) Requirement for leptin in the induction and progression of autoimmune encephalomyelitis. J Immunol 166:5909–16PubMed
86.
Otero M, Lago R, Lago F, Casanueva FF, Dieguez C, Gómez-Reino JJ, Gualillo O (2005) Leptin, from fat to inflammation: old questions and new insights. FEBS Lett 579:295–301PubMedCrossRef
87.
Romanowska M, al Yacoub N, Seidel H, Donandt S, Gerken H, Phillip S, Haritonova N, Artuc M, Schweiger S, Sterry W, Foerster J (2008) PPAR delta enhances keratinocyte proliferation in psoriasis and induces heparin-binding EGF-like growth factor. J Invest Dermatol 128:110–24PubMedCrossRef
88.
Tekin NS, Tekin IO, Barut F, Sipahi EY (2007) Accumulation of oxidized low-density lipoprotein in psoriatic skin and changes of plasma lipid levels in psoriatic patients. Mediators Inflamm 2007:78454PubMed
89.
Cerman AA, Bozkurt S, Sav A, Tulunay A, Elbaşi MO, Ergun T (2008) Serum leptin levels, skin leptin and leptin receptor expression in psoriasis. Br J Dermatol 159:820–6PubMedCrossRef
90.
Johnston A, Arnadottir S, Gudjonsson JE, Aphale A, Sigmarsdottir AA, Gunnarsson SI, Steinsson JT, Elder JT, Valdimarsson H (2008) Obesity in psoriasis: leptin and resistin as mediators of cutaneous inflammation. Br J Dermatol 159:342–50PubMedCrossRef
91.
Matarese G, Mantzoros C, La Cava A (2007) Leptin and adipocytokines: bridging the gap between immunity and atherosclerosis. Curr Pharm Des 13:3676–80PubMedCrossRef
92.
Rizzo M, Rizvi AA, Rini GB, Berneis K (2009) The therapeutic modulation of atherogenic dyslipidemis and inflammatory markers in the metabolic syndrome: what is the clinical relevance? Acta Diabetol 46:1–11PubMedCrossRef
Metadata
Title
Inflammation, Atherosclerosis, and Psoriasis
Authors
David Siegel
Sridevi Devaraj
Anupam Mitra
Siba P. Raychaudhuri
Smriti K. Raychaudhuri
Ishwarlal Jialal
Publication date
01-04-2013
Publisher
Humana Press Inc
Published in
Clinical Reviews in Allergy & Immunology / Issue 2/2013
Print ISSN: 1080-0549
Electronic ISSN: 1559-0267
DOI
https://doi.org/10.1007/s12016-012-8308-0

Other articles of this Issue 2/2013

Clinical Reviews in Allergy & Immunology 2/2013 Go to the issue

ReviewPaper

Clinical and Histologic Diagnostic Guidelines for Psoriasis: A Critical Review

ReviewPaper

A Cutting Edge Overview: Psoriatic Disease

ReviewPaper

Biologic Therapies in the Treatment of Psoriasis: A Comprehensive Evidence-Based Basic Science and Clinical Review and a Practical Guide to Tuberculosis Monitoring

ReviewPaper

Imaging in Psoriatic Arthritis

ReviewPaper

Type I Interferons: Beneficial in Th1 and Detrimental in Th17 Autoimmunity

ReviewPaper

Psoriatic Arthritis: a Critical Review
Live Webinar | 27-06-2024 | 18:00 (CEST)

Keynote webinar | Spotlight on medication adherence

Reserve your place

Live: Thursday 27th June 2024, 18:00-19:30 (CEST)

WHO estimates that half of all patients worldwide are non-adherent to their prescribed medication. The consequences of poor adherence can be catastrophic, on both the individual and population level.

Join our expert panel to discover why you need to understand the drivers of non-adherence in your patients, and how you can optimize medication adherence in your clinics to drastically improve patient outcomes.

Prof. Kevin Dolgin
Prof. Florian Limbourg
Prof. Anoop Chauhan
Developed by: Springer Medicine
Obesity Clinical Trial Summary

At a glance: The STEP trials

Read more

A round-up of the STEP phase 3 clinical trials evaluating semaglutide for weight loss in people with overweight or obesity.

Developed by: Springer Medicine

Highlights from the ACC 2024 Congress

Year in Review: Pediatric cardiology

Pediatric Cardiology Video

Watch Dr. Anne Marie Valente present the last year's highlights in pediatric and congenital heart disease in the official ACC.24 Year in Review session.

Year in Review: Pulmonary vascular disease

Cardiopulmonary Comorbidity Video

The last year's highlights in pulmonary vascular disease are presented by Dr. Jane Leopold in this official video from ACC.24.

Year in Review: Valvular heart disease

Valvular Heart Disease Video

Watch Prof. William Zoghbi present the last year's highlights in valvular heart disease from the official ACC.24 Year in Review session.

Year in Review: Heart failure and cardiomyopathies

Heart Failure Video

Watch this official video from ACC.24. Dr. Biykem Bozkurt discusses last year's major advances in heart failure and cardiomyopathies.

ACC 2024 Congress Coverage

Year in Review: Heart failure and cardiomyopathies

Heart Failure Video

Watch this official video from ACC.24. Dr. Biykem Bozkurt discusses last year's major advances in heart failure and cardiomyopathies.

Watch now

Semaglutide benefits people with type 2 diabetes and obesity-related heart failure

16-04-2024 Type 2 Diabetes News

Incentivised to exercise

11-04-2024 Lifestyle Modifications News

New intervention for STEMI-related cardiogenic shock

10-04-2024 Myocardial Infarction News

» View more highlights on the ACC 2024 congress hub page

Image Credits